LLY catalysts
Catalysts and events linked to LLY, newest first.
Do these developments change your position?
Review LLY alongside your other holdings and identify which decision deserves attention first.
Review your initial audit before choosing ongoing portfolio scanning at $79/month.
DateCardAvg 5d
- 2026-08-30Novo Nordisk Deploys Oral Wegovy and Vivani Delivery Implant Against LillyLLY NVO VANI+2.17%
- 2026-08-30Novo Nordisk Introduces Wegovy Pill and Vivani Implant to Challenge LillyLLY NVO VANI+2.17%
- 2026-08-30Novo Nordisk Introduces Oral Wegovy and Partners with Vivani on GLP-1 ImplantLLY NVO VANI+2.17%
- 2026-08-30Novo Nordisk Deploys Oral Wegovy and Vivani Delivery PartnershipLLY NVO VANI+2.17%
- 2026-08-30Novo Nordisk Launches Oral Wegovy and Partners with Vivani on Implant DeliveryLLY NVO VANI+2.17%
- 2026-08-30Eli Lilly GLP-1 Revenue Hits Nearly Two-Thirds of Sales Amid 45% Top-Line GrowthABBV LLY
- 2026-08-30Novo Nordisk Launches Oral Wegovy and Enters Vivani Drug Delivery Implant DealLLY NVO VANI+2.17%
- 2026-08-30Eli Lilly GLP-1 Portfolio Generates Two-Thirds of Total Revenue Amid 45% Top-Line GrowthABBV LLY
- 2026-08-30Eli Lilly GLP-1 Portfolio Delivers 45% Growth as Concentration Nears Two-Thirds RevenueABBV LLY
- 2026-08-30Novo Nordisk Introduces Wegovy Pill and Partners on Long-Acting ImplantLLY NVO VANI+2.17%
- 2026-08-30Novo Nordisk Launches Oral Wegovy and Partners with Vivani for GLP-1 ImplantsLLY NVO VANI+2.17%
- 2026-08-07Nxera Pharma Reports Strong Q2 Revenue on R&D MilestonesLLY
- 2026-08-07Nxera Pharma Revenue Jumps on R&D Milestones with AbbVie and LillyABBV LLY
- 2026-08-06Eli Lilly rises 5% on surging obesity drug sales and Q2 beat → Bullish LLYLLY
- 2026-08-06Eli Lilly rises 4.8% on 91% Mounjaro sales growth and Q2 beat → Bullish LLYLLY
- 2026-08-06Eli Lilly Surges 5% on 91% Mounjaro Sales Growth → Bullish LLYLLY
- 2026-08-06Eli Lilly shares rise 5% on surging Mounjaro and Zepbound sales → Bullish LLYLLY
- 2026-08-06Eli Lilly rises 5% on surging obesity drug sales and Q2 beatLLY XLV+2.39%
- 2026-08-06Eli Lilly Surges 5% on 91% Mounjaro Sales GrowthLLY
- 2026-08-06Eli Lilly rises 4.8% on 91% Mounjaro sales growth and Q2 beatLLY
- 2026-08-06Eli Lilly shares rise 5% on surging Mounjaro and Zepbound salesLLY XLV+2.39%
- 2026-08-06Eli Lilly Surges 5% on 91% Mounjaro Sales GrowthLLY
- 2026-08-06Eli Lilly rises 4.8% on 91% Mounjaro sales growth and Q2 beatLLY
- 2026-08-06Eli Lilly rises 5% on surging obesity drug sales and Q2 beatLLY XLV+2.39%
- 2026-08-06Eli Lilly shares rise 5% on surging Mounjaro and Zepbound salesLLY XLV+2.39%
- 2026-07-22Novo Nordisk Files Federal Lawsuit Against Eli Lilly Over GLP-1 AdsLLY NVO+7.03%
- 2026-07-22Study: GLP-1 drugs linked to lower alcohol-related hospitalizationsLLY NVO+7.03%
- 2026-07-22Study: GLP-1 drugs linked to lower alcohol-related hospitalizationsLLY NVO+7.03%
- 2026-07-22Novo Nordisk sues Eli Lilly over 'deceptive' GLP-1 advertisingLLY NVO+7.03%
- 2026-07-22Novo Nordisk Sues Eli Lilly Over GLP-1 AdsLLY NVO+7.03%
- 2026-07-20Pfizer Targets $100B Weight-Loss Market via Metsera AcquisitionLLY PFE
- 2026-07-20Pfizer Targets $100B Weight-Loss Market via Metsera AcquisitionLLY PFE
- 2026-07-13Eli Lilly Raises 2026 Guidance to $82-85B on Mounjaro/Zepbound GrowthLLY
- 2026-07-13Eli Lilly Raises 2026 Guidance to $82-85B on Mounjaro/Zepbound GrowthLLY
- 2026-07-11Novo Nordisk Down 75% from Peak Amid Value Trap DebateLLY NVO+1.70%
- 2026-06-30Big Pharma Enters 'Merger Mania' as $300B Patent Cliff LoomsGS LLY+1.81%
- 2026-06-30Big Pharma Enters 'Merger Mania' as $300B Patent Cliff LoomsGS LLY+1.81%
- 2026-06-30Big Pharma 'Merger Mania' Driven by $300B Patent CliffLLY XBI+2.98%
- 2026-06-17GLP-1 Market Projected to Reach $95.3B by 2035LLY NVO+9.47%
- 2026-06-17GLP-1 Market Projected to Reach $95.3B by 2035; LLY and NVO LeadLLY NVO+9.47%
- 2026-05-27Eli Lilly expands into vaccines with billion-dollar acquisition waveLLY XBI-3.44%
- 2026-05-26Eli Lilly's Mounjaro Dominates International GLP-1 MarketLLY NVO-2.87%
- 2026-05-26Morgan Stanley highlights Eli Lilly's GLP-1 dominance over Novo NordiskLLY NVO-2.87%
- 2026-05-21Eli Lilly Obesity Drug Retatrutide Shows 28.3% Weight Loss in Phase 3 TrialLLY NVO XBI+2.81%
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.